Inhibrx Biosciences Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Inhibrx Biosciences Inc has an operating margin of -165724.0%, meaning the company retains $-165724 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -12178.9% the prior year.
Inhibrx Biosciences Inc's revenue declined 88.9% year-over-year, from $1.8M to $200K. This contraction results in a growth score of 0/100.
Inhibrx Biosciences Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.94, Inhibrx Biosciences Inc holds $3.94 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Inhibrx Biosciences Inc generated -$194.4M in operating cash flow, capex of $2.6M consumed most of it, leaving -$197.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Inhibrx Biosciences Inc earns a strong 1263.3% return on equity (ROE), meaning it generates $1263 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Inhibrx Biosciences Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Inhibrx Biosciences Inc generates $-0.12 in operating cash flow (-$194.4M OCF vs $1.7B net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Inhibrx Biosciences Inc earns $-24.6 in operating income for every $1 of interest expense (-$331.4M vs $13.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Inhibrx Biosciences Inc (INBX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Inhibrx Biosciences Inc generated $200K in revenue in fiscal year 2024. This represents a decrease of 88.9% from the prior year.
Inhibrx Biosciences Inc's EBITDA was -$329.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 51.0% from the prior year.
Inhibrx Biosciences Inc generated -$197.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 0.5% from the prior year.
Inhibrx Biosciences Inc reported $1.7B in net income in fiscal year 2024. This represents an increase of 799.2% from the prior year.
Inhibrx Biosciences Inc earned $112.62 per diluted share (EPS) in fiscal year 2024. This represents an increase of 649.9% from the prior year.
Inhibrx Biosciences Inc held $152.6M in cash against $0 in long-term debt as of fiscal year 2024.
Inhibrx Biosciences Inc had 14M shares outstanding in fiscal year 2024. This represents a decrease of 69.4% from the prior year.
Inhibrx Biosciences Inc's operating margin was -165724.0% in fiscal year 2024, reflecting core business profitability. This is down 153545.1 percentage points from the prior year.
Inhibrx Biosciences Inc's net profit margin was 843786.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 857194.9 percentage points from the prior year.
Inhibrx Biosciences Inc's ROE was 1263.3% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Inhibrx Biosciences Inc invested $203.7M in research and development in fiscal year 2024. This represents an increase of 6.3% from the prior year.
Inhibrx Biosciences Inc invested $2.6M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 43.5% from the prior year.
INBX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $1.3M | $0-100.0% | $100K0.0% | $100K | $0 | N/A | $119K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $28.5M+28.1% | $22.3M-39.6% | $36.9M+10.5% | $33.4M-50.7% | $67.6M+5.9% | $63.9M | N/A | $38.1M |
| SG&A Expenses | $5.3M-17.8% | $6.4M+6.6% | $6.0M-63.8% | $16.7M-82.2% | $93.4M+836.1% | $10.0M | N/A | $7.9M |
| Operating Income | -$33.8M-23.5% | -$27.4M+36.2% | -$42.9M+14.1% | -$49.9M+69.0% | -$160.9M-117.9% | -$73.8M | N/A | -$45.8M |
| Interest Expense | $3.2M+1.3% | $3.1M+16.8% | $2.7M | $0-100.0% | $5.4M-34.1% | $8.1M | N/A | $8.1M |
| Income Tax | $0-100.0% | $2K | $0 | $0-100.0% | $2K | $0 | N/A | $2K |
| Net Income | -$35.3M-23.0% | -$28.7M+33.8% | -$43.3M+9.5% | -$47.9M-102.6% | $1.9B+2460.6% | -$78.7M | N/A | -$51.8M |
| EPS (Diluted) | $-2.28-23.2% | $-1.85+33.9% | $-2.80+34.1% | $-4.25-103.4% | $125.48+2274.7% | $-5.77 | N/A | $-4.39 |
INBX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $177.5M-16.3% | $212.1M-12.6% | $242.6M+34.2% | $180.8M-30.0% | $258.4M | N/A | $307.9M | N/A |
| Current Assets | $161.4M-16.8% | $194.0M-13.2% | $223.4M+39.3% | $160.4M-33.7% | $242.1M | N/A | $295.4M | N/A |
| Cash & Equivalents | $153.1M-17.9% | $186.6M-13.8% | $216.5M+41.9% | $152.6M-32.7% | $226.9M-10.1% | $252.5M-9.2% | $277.9M-17.6% | $337.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $140.6M-2.0% | $143.6M-3.1% | $148.2M+214.1% | $47.2M+20.8% | $39.1M | N/A | $264.4M | N/A |
| Current Liabilities | $36.0M-7.6% | $38.9M-10.8% | $43.6M+7.1% | $40.7M+4.3% | $39.1M | N/A | $56.3M | N/A |
| Long-Term Debt | $99.9M+0.6% | $99.3M+0.6% | $98.7M | $0 | $0 | N/A | $207.0M | N/A |
| Total Equity | $36.8M-46.3% | $68.6M-27.4% | $94.4M-29.3% | $133.6M-39.1% | $219.4M+1796.3% | $11.6M-73.4% | $43.5M-66.4% | $129.6M |
| Retained Earnings | -$213.4M-19.8% | -$178.1M-19.2% | -$149.4M-40.8% | -$106.1M-636.9% | -$14.4M | N/A | -$613.7M | N/A |
INBX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.8M-12.9% | -$30.0M+16.6% | -$35.9M+17.9% | -$43.7M+23.8% | -$57.4M+9.0% | -$63.0M-11.0% | -$56.8M-4.7% | -$54.2M |
| Capital Expenditures | $10K | $0-100.0% | $21K+31.3% | $16K-98.7% | $1.2M+8.6% | $1.1M-67.5% | $3.4M+324.4% | $811K |
| Free Cash Flow | -$33.8M-13.0% | -$30.0M+16.6% | -$35.9M+17.9% | -$43.7M+25.3% | -$58.6M+8.7% | -$64.2M-6.5% | -$60.3M-9.5% | -$55.1M |
| Investing Cash Flow | -$7K | $0+100.0% | -$21K-31.3% | -$16K+98.7% | -$1.2M-8.6% | -$1.1M+67.5% | -$3.4M-324.4% | -$811K |
| Financing Cash Flow | $352K | $0-100.0% | $99.8M | $0-100.0% | $33.0M-14.9% | $38.7M+4403.3% | $860K-99.6% | $199.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
INBX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -2106.8% | N/A | -49928.0%+110970.0pp | -160898.0% | N/A | N/A | -38510.1% |
| Net Margin | N/A | -2204.2% | N/A | -47865.0%-1905876.0pp | 1858011.0% | N/A | N/A | -43520.2% |
| Return on Equity | N/A | N/A | N/A | N/A | 847.0% | N/A | N/A | N/A |
| Return on Assets | -19.9%-6.4pp | -13.5%+4.3pp | -17.8%+8.6pp | -26.5%-745.5pp | 719.0% | N/A | N/A | N/A |
| Current Ratio | 4.49-0.5 | 4.98-0.1 | 5.12+1.2 | 3.94-2.3 | 6.20 | N/A | 5.25 | N/A |
| Debt-to-Equity | 2.71+1.3 | 1.45+0.4 | 1.04+1.0 | 0.000.0 | 0.00 | N/A | 4.76 | N/A |
| FCF Margin | N/A | -2304.1% | N/A | -43736.0%+14837.0pp | -58573.0% | N/A | N/A | -46265.6% |
Similar Companies
Frequently Asked Questions
What is Inhibrx Biosciences Inc's annual revenue?
Inhibrx Biosciences Inc (INBX) reported $200K in total revenue for fiscal year 2024. This represents a -88.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Inhibrx Biosciences Inc's revenue growing?
Inhibrx Biosciences Inc (INBX) revenue declined by 88.9% year-over-year, from $1.8M to $200K in fiscal year 2024.
Is Inhibrx Biosciences Inc profitable?
Yes, Inhibrx Biosciences Inc (INBX) reported a net income of $1.7B in fiscal year 2024, with a net profit margin of 843786.0%.
What is Inhibrx Biosciences Inc's earnings per share (EPS)?
Inhibrx Biosciences Inc (INBX) reported diluted earnings per share of $112.62 for fiscal year 2024. This represents a 649.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Inhibrx Biosciences Inc's EBITDA?
Inhibrx Biosciences Inc (INBX) had EBITDA of -$329.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Inhibrx Biosciences Inc have?
As of fiscal year 2024, Inhibrx Biosciences Inc (INBX) had $152.6M in cash and equivalents against $0 in long-term debt.
What is Inhibrx Biosciences Inc's operating margin?
Inhibrx Biosciences Inc (INBX) had an operating margin of -165724.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Inhibrx Biosciences Inc's net profit margin?
Inhibrx Biosciences Inc (INBX) had a net profit margin of 843786.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Inhibrx Biosciences Inc's return on equity (ROE)?
Inhibrx Biosciences Inc (INBX) has a return on equity of 1263.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Inhibrx Biosciences Inc's free cash flow?
Inhibrx Biosciences Inc (INBX) generated -$197.0M in free cash flow during fiscal year 2024. This represents a 0.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Inhibrx Biosciences Inc's operating cash flow?
Inhibrx Biosciences Inc (INBX) generated -$194.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Inhibrx Biosciences Inc's total assets?
Inhibrx Biosciences Inc (INBX) had $180.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Inhibrx Biosciences Inc's capital expenditures?
Inhibrx Biosciences Inc (INBX) invested $2.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Inhibrx Biosciences Inc spend on research and development?
Inhibrx Biosciences Inc (INBX) invested $203.7M in research and development during fiscal year 2024.
How many shares does Inhibrx Biosciences Inc have outstanding?
Inhibrx Biosciences Inc (INBX) had 14M shares outstanding as of fiscal year 2024.
What is Inhibrx Biosciences Inc's current ratio?
Inhibrx Biosciences Inc (INBX) had a current ratio of 3.94 as of fiscal year 2024, which is generally considered healthy.
What is Inhibrx Biosciences Inc's debt-to-equity ratio?
Inhibrx Biosciences Inc (INBX) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inhibrx Biosciences Inc's return on assets (ROA)?
Inhibrx Biosciences Inc (INBX) had a return on assets of 933.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Inhibrx Biosciences Inc's cash runway?
Based on fiscal year 2024 data, Inhibrx Biosciences Inc (INBX) had $152.6M in cash against an annual operating cash burn of $194.4M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Inhibrx Biosciences Inc's Piotroski F-Score?
Inhibrx Biosciences Inc (INBX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inhibrx Biosciences Inc's earnings high quality?
Inhibrx Biosciences Inc (INBX) has an earnings quality ratio of -0.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Inhibrx Biosciences Inc cover its interest payments?
Inhibrx Biosciences Inc (INBX) has an interest coverage ratio of -24.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Inhibrx Biosciences Inc?
Inhibrx Biosciences Inc (INBX) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.